This discovery indicated that blocking PD-L1 might decrease the percentage of some activated or cytotoxic T cell subpopulations and this might be one of the reasons why the expression of tumor PD-L1 may not accurately predict the outcome of anti-PD-1/PD-L1 therapies. The gene discussed is PDCD1; the disease is neoplasm.